Diallyl trisulfide-induced G2-M phase cell cycle arrest in human prostate cancer cells is caused by reactive oxygen species-dependent destruction and hyperphosphorylation of Cdc25C

Oncogene

Volumn 24, Issue 41, 2005, Pages 6256-6268

  Xiao, Dong ^a   Herman Antosiewicz, Anna ^a   Antosiewicz, Jedrzej ^a   Xiao, Hui ^a   Brisson, Marni ^a   Lazo, John S ^a   Singh, Shivendra V ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cdc25C; Cell cycle arrest; Chemoprevention; Diallyl trisulfide; Prostate cancer; ROS

Indexed keywords

ACETYLCYSTEINE; ANTISENSE OLIGONUCLEOTIDE; CYCLIN B1; CYCLIN DEPENDENT KINASE 3; DIALLYL TRISULFIDE; PROTEIN P21; PROTEIN TYROSINE PHOSPHATASE; REACTIVE OXYGEN METABOLITE; SERINE; TYROSINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ALLYL COMPOUNDS; CDC25 PHOSPHATASE; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE, TUMOR; G2 PHASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; SERINE; SULFIDES;

ALLIUM SATIVUM;

EID: 28044435379     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1208759     Document Type: Article

References (67)

1. Agarwal KC. (1996). Med. Res. Rev., 16, 111-124.
2. Block E. (1992). Angew. Chem. Int. Ed. Engl., 31, 1135-1178.
3. Bookstein R, Shew J, Chen P, Scully P and Lee W. (1990). Science, 247, 712-715.
4. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B. (1998). Science, 282, 1497-1501.
5. Campbell CL, Savarese DMF, Quesenberry PJ and Savarese TM. (1999). Int. J. Cancer, 80, 868-874.
6. Challier B, Perarnau JM and Viel JF. (1998). Eur. J. Epidemiol., 14, 737-747.
7. Charrier-Savournin FB, Chateau M, Gire V, Sedivy J, Piette J and Dulic V. (2004). Mol. Biol. Cell, 15, 3965-3976.
8. Chen L, Hodge GB, Guarda LA, Welch JL, Greenberg NM and Chai KX. (2001). Prostate, 48, 93-103.
9. Choi S and Singh SV. (2005). Cancer Res., 65, 2035-2043.
10. Dausch JG and Nixon DW. (1990). Prev. Med., 19, 346-361.
11. Draetta G and Eckstein J. (1997). Biochim. Biophys. Acta, 1332, M53-M63.
12. Druesne N, Pagniez A, Mayeur C, Thomas M, Cherbuy C, Duee P, Martel P and Chaumontet C. (2004). Carcinogenesis, 25, 1227-1236.
13. Dulic V, Stein GH, Far DF and Reed SI. (1998). Mol. Cell. Biol., 18, 546-557.
14. Falck J, Mailand N, Syljuasen RG, Bartek J and Lukas J. (2001). Nature, 410, 842-847.
15. Filomeni G, Aquilano K, Rotilio G and Ciriolo MR. (2003). Cancer Res., 63, 5940-5949.
16. Freemerman AJ, Vrana JA, Tombes RM, Jiang H, Chellappan SP, Fisher PB and Grant S. (1997). Leukemia, 11, 504-513.
17. Furnari B, Rhind N and Russell P. (1997). Science, 277, 1495-1497.
18. Gao CM, Takezaki T, Ding JH, Li MS and Tajima K. (1999). Jpn. J. Cancer Res., 90, 614-621.
19. Garraway LA, Lin D, Signoretti S, Waltregny D, Dilks J, Bhattacharya N and Loda M. (2003). Prostate, 55, 206-218.
20. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ. (1993). Cell, 75, 805-816.
21. Herman-Antosiewicz A and Singh SV. (2004). Mutat. Res., 555, 121-131.
22. Hsing AW, Chokkalingam AP, Gao YT, Madigan MP, Deng J, Gridley G and Fraumeni JF. (2002). J. Natl. Cancer Inst., 94, 1648-1651.
23. Knowles LM and Milner JA. (1998). Nutr. Cancer, 30, 169-174.
24. Knowles LM and Milner JA. (2000). Carcinogenesis, 21, 1129-1134.
25. Kwon KB, Yoo SJ, Ryu DG, Yang JY, Rho HW, Kim JS, Park JW, Kim HR and Park BH. (2002). Biochem. Pharmacol., 63, 41-47.
26. Lan H and Lu Y. (2004). Acta Pharmacol. Sin., 25, 219-225.
27. Li Y and Lu Y. (2002). DNA Cell Biol., 21, 771-780.
28. Mailand N, Falck J, Lukas C, Syljuasen RG, Welcker M, Bartek J and Lukas J. (2000). Science, 288, 1425-1429.
29. Matsuoka S, Huang M and Elledge SJ. (1998). Science, 282, 1893-1897.
30. Milner JA. (2001). J. Nutr., 131, 1027s-1031s.
31. Mitchell A, Abel P, Ware M, Stamp G and Lalani E. (2000). BJU Int., 85, 932-944.
32. Molinari M. (2000). Cell Prolif., 33, 261-274.
33. Molinari M, Mercurio C, Dominguez J, Goubin F and Draetta GF. (2000). EMBO Rep., 1, 71-79.
34. Nagae S, Ushijima M, Hatono S, Imai J, Kasuga S, Matsuura H, Itakura Y and Higashi Y. (1994). Planta Med., 60, 214-217.
35. Nakagawa H, Tsuta K, Kiuchi K, Senzaki H, Tanaka K, Hioki K and Tsubura A. (2001). Carcinogenesis, 22, 891-897.
36. Nakamoto T, Chang C, Li A and Chodak GW. (1992). Cancer Res., 52, 571-577.
37. Narayanan PK, Goodwin EH and Lehnert BE. (1997). Cancer Res., 57, 3963-3971.
38. Peng CY, Graves PR, Ogg S, Thoma RS, Byrnes MJ, Wu Z, Stephenson MT and Piwnica-Worms H. (1998). Cell Growth Differ., 9, 197-208.
39. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS and Piwnica-Worms H. (1997). Science, 277, 1501-1505.
40. Pines J and Hunter T. (1991). J. Cell Biol., 115, 1-17.
41. Reddy BS, Rao CV, Rivenson A and Kelloff G. (1993). Cancer Res., 53, 3493-3498.
42. Robert V, Mouille B, Mayeur C, Midland M and Blachier F. (2001). Carcinogenesis, 22, 1155-1161.
43. Rothe G and Valet GJ. (1990). J. Leukoc. Biol., 47, 440-448.
44. Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H and Elledge SJ. (1997). Science, 277, 1497-1501.
45. Savitsky PA and Finkel T. (2002). J. Biol. Chem., 277, 20535-20540.
46. Schaffer EM, Liu JZ, Green J, Dangler CA and Milner JA. (1996). Cancer Lett., 102, 199-204.
47. Sherwood SW, Rush DF, Kung AL and Schimke RT. (1994). Exp. Cell Res., 211, 275-281.
48. Shirin H, Pinto JT, Kawabata Y, Soh JW, Delohery T, Moss SF, Murty V, Rivlin RS, Holt PR and Weinstein IB. (2001). Cancer Res., 61, 725-731.
49. Singh SV, Herman-Antosiewicz A, Singh AV, Lew KL, Srivastava SK, Kamath R, Brown KD, Zhang L and Baskaran R. (2004). J. Biol. Chem., 279, 25813-25822.
50. Sparnins VL, Barany G and Wattenberg LW. (1988). Carcinogenesis, 9, 131-134.
51. Sumiyoshi H and Wargovich MJ. (1990). Cancer Res., 50, 5084-5087.
52. Sundaram SG and Milner JA. (1996). Carcinogenesis, 17, 669-673.
53. Suzui N, Sugie S, Rahman KM, Ohnishi M, Yoshimi N, Wakabayashi K and Mori H. (1997). Jpn. J. Cancer Res., 88, 705-711.
54. Takahashi S, Hakoi K, Yada H, Hirose M, Ito N and Fukushima S. (1992). Carcinogenesis, 13, 1513-1518.
55. Taylor WR and Stark GR. (2001). Oncogene, 20, 1803-1815.
56. Vogt A, Tamura K, Watson S and Lazo JS. (2000). J. Pharmacol. Exp. Therapeut., 294, 1070-1075.
57. Wargovich MJ. (1987). Carcinogenesis, 8, 487-489.
58. Wargovich MJ, Woods C, Eng VWS, Stephens LC and Gray K. (1988). Cancer Res., 48, 6872-6875.
59. Wattenberg LW, Sparnins VL and Barany G. (1989). Cancer Res., 49, 2689-2692.
60. Webber M, Bello D and Quader S. (1997a). Prostate, 30, 58-64.
61. Webber M, Bello D and Quader S. (1997b). Prostate, 30, 136-142.
62. Widrow RJ, Rabinovitch PS, Cho K and Laird CD. (1997). Cytometry, 27, 250-254.
63. Winters ZE, Ongkeko WM, Harris AL and Norbury CJ. (1998). Oncogene, 17, 673-684.
64. Xiao D, Choi S, Johnson DE, Vogel VG, Johnson CS, Trump DL, Lee YJ and Singh SV. (2004). Oncogene, 23, 5594-5606.
65. Xiao D, Pinto JT, Soh JW, Deguchi A, Gundersen GG, Palazzo AF, Yoon JT, Shirin H and Weinstein IB. (2003). Cancer Res., 63, 6825-6837.
66. Xiao D and Singh SV. (2002). Cancer Res., 62, 3615-3619.
67. You WC, Blot WJ, Chang YS, Ershow A, Yang ZT, An Q, Henderson BE, Fraumeni JF and Wang TG. (1989). J. Natl. Cancer Inst., 81, 162-164.